by Stephane Cailmail | 7 Feb 2020 | Actualités générales, General news, Publications, Research
Immunotherapy is a treatment that aims to educate our immune system against cancer cells. This treatment resulted in a long-term response in patients with metastatic melanoma (40-60%) with in some cases total tumour regression. The challenge is now that the maximum...
by Sébastien Guibert | 23 Jan 2020 | General news, Research
A collaboration in Toulouse, France, between Pierre Fabre Research Institute, the University Cancer Institute and the Cancer Research Center aims to collect and integrate data to improve and personalize immuno-therapies. Immunotherapies are imposing themselves as a...
by Stephane Cailmail | 6 Dec 2019 | General news, Research
A multi-year framework agreement has just been signed by 3 major stakeholders present on the Oncopole campus in Toulouse: the Pierre Fabre Research Institute (IRPF), the Centre de Recherches en Cancérologie de Toulouse (CRCT-Inserm) and the Institut Universitaire du...
by Sébastien Guibert | 27 Nov 2019 | General news, Research
Prof. Hervé Avet-Loiseau, head of the “Myeloma Genomics” unit at IUCT-Oncopole and the “Oncogenomics and immunology of myeloma” team at CRCT is on Clarivate Analytics’ list of the most influential researchers of the past decade. This is a...
by Sébastien Guibert | 15 Jan 2019 | General news, Research
IMLINFO is a cross-border network of personalized immunotherapies for Non-Hodgkin’s lymphomas (NHL) involving 7 organizations located in Spain and France. Its main objective is to determine the efficacy of new immunotherapy treatments through the creation of a...
by Sébastien Guibert | 3 Apr 2018 | General news, Research
Discover in this France 3 TV report the collaboration between the CRCT team led by Dr. Pierre Cordelier and the Toulouse start-up Neovirtech: a therapeutic innovation opening up new perspectives in the treatment of cancer....
